KMDA — KAMADA (Healthcare >> Drug Manufacturers - Specialty & Generic)
KMDA FAQ
What is KMDA's P/E ratio?
KAMADA (KMDA) currently trades at a P/E ratio of 20.95.
What is KMDA's ROE?
KAMADA reports a Return on Equity (ROE) of 7.85%.
What is KMDA's dividend yield?
KAMADA offers a dividend yield of 3.39%.
What is KMDA's Deepscope Quality Score?
Deepscope rates KMDA's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy KMDA?
Deepscope's AI Timing Score for KMDA is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does KMDA belong to?
KAMADA is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange.
|
USD 7.17
Price
-0.21
(-2.85%)
Day Change
|
|
|---|
KMDA, the overall quality is not good ( Quality = 46) and the timing to buy is ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
44% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 92 |
| Magic Formula Rank by ROA |
1525
|
| Magic Formula Rank by ROE |
1525
|
| Magic Formula Rank by ROIC |
1493
|
| Price | 7.17 |
| PBV / Sector |
1.64 / 2.76
|
| Earning Per Share | 0.34 |
| PE / Sector |
20.95 / 23.64
|
| PEG or PE/Growth / Sector |
-0.21 / 0.13
|
| Average 1M Daily Value |
0.47 M
GREAT
|
| Average 1W Daily Value |
0.38 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
60% |
| Return to Investors |
|
62% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:48 |
| Symbol | KMDA |
| Name | KAMADA |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 57.69 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 426.68 / 9,835.56 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 2 Holzman Street, Rehovot, Israel, 7670402
Phone: 972 8 940 6472
Website: https://www.kamada.com
Employees: 462
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
Google